Literature DB >> 1725424

Down-regulation of endothelin-1 receptors by protein kinase C in streptozotocin diabetic rats.

M Awazu1, R E Parker, B R Harvie, I Ichikawa, V Kon.   

Abstract

The vasoconstrictor response is defective in diabetes mellitus (DM). Activation of protein kinase C (PKC) is also known to prevail in diabetes mellitus, and it is thought to be secondary to abnormal diacylglycerol metabolism. To ascertain whether this PKC activation in diabetes underlies the vasomotor defect by regulating biological receptors, we studied the characteristics of the receptor for endothelin (ET), "the vasoconstrictor of injury." For this purpose, diabetes was induced in rats by intravenous streptozotocin. One to 2 weeks after streptozotocin treatment (average glucose at time of experiments: 518 mg/dl), glomeruli were isolated and assessed for ET receptor and PKC activity. ET receptor characteristics were also assessed following infusion of a specific PKC inhibitor, 1-(5-isoquinolinesulfonyl)piperazine (CI). For comparison, nondiabetic controls with and without PKC inhibitor were studied. No differences in high-affinity ET-1 receptor (ER-1) characteristics were found among the diabetic and normal rats. In contrast, receptor density for the lower-affinity receptor (ER-2) was significantly depressed in DM without changes in the equilibrium dissociation constant. Infusion of CI 20 min before glomerular harvesting did not affect the glomerular PKC activity in controls (particulate: 28.0 +/- 4.0% of total activity to 22.0 +/- 3.9%, n = 3). In contrast, in diabetes mellitus rats infused with CI, PKC activity decreased (particulate: from 44.7 +/- 2.9% of total activity to 18.5 +/- 3.2%, n = 3, p less than 0.05). This CI-induced suppression of PKC in DM was accompanied by complete reversal in down-regulation of ER-2 receptors. Thus, DM is characterized by down-regulation in low-affinity ET-1 receptors. Furthermore, this receptor down-regulation can be reversed by abolishing abnormally enhanced PKC activity. These results indicate that abnormal activation of PKC may underlie the profoundly vasodilative status and defective vasoconstrictor response characterizing DM.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1725424     DOI: 10.1097/00005344-199100177-00142

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

Review 1.  Role of endothelin in diabetic vascular complications.

Authors:  H C Lam
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

2.  Sex differences in renal medullary endothelin receptor function in angiotensin II hypertensive rats.

Authors:  Wararat Kittikulsuth; Jennifer S Pollock; David M Pollock
Journal:  Hypertension       Date:  2011-06-06       Impact factor: 10.190

3.  Osmolar regulation of endothelin signaling in rat renal medullary interstitial cells.

Authors:  M A Vernace; P F Mento; M E Maita; E P Girardi; M D Chang; E P Nord; B M Wilkes
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

4.  The potential contribution of endothelin-1 to neurovascular abnormalities in streptozotocin-diabetic rats.

Authors:  N E Cameron; K C Dines; M A Cotter
Journal:  Diabetologia       Date:  1994-12       Impact factor: 10.122

5.  Hyperosmolality-induced abnormal patterns of calcium mobilization in smooth muscle cells from non-diabetic and diabetic rats.

Authors:  R Wang; Y Liu; R Sauvé; M B Anand-Srivastava
Journal:  Mol Cell Biochem       Date:  1998-06       Impact factor: 3.396

6.  Protein kinase C inhibitors enhance endothelin-1 and attenuate vasopressin and angiotensin II evoked [Ca2+]i elevation in the rat cardiomyocyte.

Authors:  Y Xu; L Sandirasegarane; V Gopalakrishnan
Journal:  Br J Pharmacol       Date:  1993-01       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.